BTN3A1/BTN2A1 Binding Modulators for Stable Vγ9Vδ2 T Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing small molecules that bind to butyrophilin 3A1 (BTN3A1) do not effectively activate Vγ9Vδ2 T cells, and compounds like HMBPP have poor stability and drugability, limiting their in vivo activity and clinical application.
Innovation Solution
Development of small molecule compounds that promote the binding of the intracellular B30.2 domains of BTN3A1 and BTN2A1, enhancing Vγ9Vδ2 T cell activation, with improved stability and drugability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HMBPP is used to activate BTN3A1/BTN2A1, then T cell activation activity is enhanced, but plasma stability and drugability deteriorate
Solution Approach 1:
The patent employs short-chain alkyl groups (methyl, ethyl, propyl) and simple heterocyclic structures that provide sufficient biological activity while maintaining better plasma stability compared to HMBPP. These simplified molecular structures act as effective but more stable alternatives to the natural product HMBPP.
Solution Approach 2:
The patent systematically modifies molecular parameters including replacing the diene system with carbonyl groups, adjusting alkyl chain lengths, and varying heterocyclic substituents to optimize the balance between T cell activation potency and plasma stability. This parameter optimization enables compounds to achieve both high activity and improved drugability.
2Measurement precision
If small molecules bind only to BTN3A1 B30.2 domain, then binding specificity is improved, but biological function deteriorates
Solution Approach 1:
The patent designs small molecules that act as intermediaries bridging BTN3A1 and BTN2A1. The compounds bind to BTN3A1 first, then facilitate the formation of the BTN3A1-BTN2A1 heterodimer, thereby mediating the interaction between the two proteins and enabling T cell activation functionality that requires both proteins.
Solution Approach 2:
The small molecules perform preliminary binding to BTN3A1's B30.2 domain, which then induces conformational changes or facilitates recruitment of BTN2A1. This preliminary action prepares the system for subsequent heterodimer formation and T cell activation, separating the binding event from the functional outcome.
3Ease of manufacture
If compound structure is simplified for drugability, then manufacturing and stability are improved, but binding activity deteriorates
Solution Approach 1:
The patent extracts the essential pharmacophoric elements from HMBPP's complex structure, retaining only the critical components needed for BTN3A1 binding and T cell activation. By removing non-essential portions of the molecule and simplifying the structure to core carbonyl-heterocyclic-alkyl motifs, the compounds achieve better drugability while preserving key biological activities.
Data Source
Figure 1
Figure 2
AI summary
A compound of formula (I) or a pharmaceutically acceptable salt, enantiomer, diastereoisomer, solvate, hydrate, polymorph or an isotopic variant thereof. The compound can promote the binding of butyrophilin 3A1/2A1, and the definition of each group in formula (I) is as detailed in the description and the claims. The present invention further relates to a pharmaceutical composition containing the compound of formula (I) and the use thereof in clinical treatments.